|
|
Adding/expanding MOUD treatment in primary care, other general medical and behavioral/mental health settings (Brooklyn and Sigmon, 2017; Heinzerling et al., 2016; National Academies of Sciences Engineering and Medicine et al., 2019; Townley and Dorr, 2017) and in specialty addiction/ substance use disorder treatment settings and recovery programs (Clark et al., 2010; SAMHSA-HRSA Center for Integrated Health Solutions, 2014) |
-
•
Providers Clinical Support System SUD 101 Curriculum (Providers Clinical Support System, 2019b)
-
•
National Academy for Science, Engineering and Medicine: Medication for Opioid Use Disorder Saves Lives (National Academies of Sciences Engineering and Medicine et al., 2019)
-
•
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder (Wakeman et al., 2020)
-
•
Clinical Guidelines for Use of Depot Buprenorphine in the Treatment of Opioid Dependence (New South Wales Ministry of Health, 2019)
-
•
Providers Clinical Support System Primer on Antagonist-Based Treatment of Opioid Use Disorder in the Office Setting (Providers Clinical Support System, 2017b)
-
•
SAMHSA: Clinical use of extended-release injectable naltrexone in the treatment of Opioid Use Disorder: A Brief Guide (Substance Abuse and Mental Health Services Administration, 2015a)
-
•
American Academy of Addiction Psychiatry, State Targeted Response Technical Assistance Consortium Opioid Response Network (American Academy of Addiction Psychiatry and State Targeted Response Technical Assistance Consortium, 2018)
-
•
Project ECHO (Boston Medical Center, 2019b; Northeast Ohio Medical University, 2019; Project ECHO Cincinnati, 2019; University of New Mexico, 2019)
-
•
SAMHSA Buprenorphine Practitioner Locator (Substance Abuse and Mental Health Services Administration, 2020b)
-
•
American Society of Addiction Medicine: Live & Online CME Trainings (American Society of Addiction Medicine, 2019a)
-
•
Harvard Medical School free, accredited online courses in Opioid Use Disorder Education
-
•
MOUD Implementation Checklist (SAMHSA-HRSA Center for Integrated Health Solutions, 2020)
-
•
Expanding the Use of Medications to Treat Individuals with Substance Use Disorders (SAMHSA-HRSA Center for Integrated Health Solutions, 2014)
-
•
Procedures for Medication-Assisted Treatment of Alcohol or Opioid Dependence in Primary Care (Heinzerling et al., 2016)
-
•
Getting Started with MOUD with Lessons from Advancing Recovery (Clark et al., 2010)
-
•
SAMHSA TIP 63: Medications for OUD (Substance Abuse and Mental Health Services Administration, 2020d)
-
•
SAMHSA MAT Guide for Pregnant Women with OUD (Substance Abuse and Mental Health Services Administration, 2018a)
-
•
SAMHSA TIP 42: Substance Abuse Treatment for Persons with Co-Occurring Disorders (Substance Abuse and Mental Health Services Administration, 2020f)
-
•
American Psychological Association: The Opioid Guide (American Psychological Association Cross-Divisional Taskforce on Clinical Responses to the Opioid Crisis, 2019)
-
•
Integrating Buprenorphine Treatment for OUD in Primary Care (Cunningham and Lum, 2017)
-
•
Medication-assisted treatment models of care for opioid use disorder in primary care settings (Chou et al., 2016b)
-
•
Boston Medical Center Office Based Addiction Treatment TTA and Addiction CHAT Live (Boston Medical Center, 2019a)
-
•
SAMHSA Apply for a Practitioner Waiver (Substance Abuse and Mental Health Services Administration, 2020a)
-
•
American Academy of Addiction Psychiatry 8 h and 24 h Waiver Training (American Academy of Addiction Psychiatry, 2019)
-
•
American Society of Addiction Medicine Waiver Qualifying Training (American Society of Addiction Medicine, 2019c)
-
•
Providers Clinical Support System Overview of Medication Assisted Treatment (Providers Clinical Support System, 2020b)
-
•
Provider Clinical Support System Mentoring Program (Providers Clinical Support System, 2020c)
-
•
Boston Medical Center Office Based Addiction Treatment Clinical Tools and Forms (Boston Medical Center, 2019d)
-
•
California Bridge (California Department of Health Care Services, 2018) and Project “Support for Hospital Opioid Use Treatment” (Project SHOUT and California Health Care Foundation, 2018)
-
•
Buprenorphine Home Induction smart phone application(Amston Studio LLC, 2019)
-
•
National Institute on Drug Abuse Home Induction guide (National Institute on Drug Abuse, 2019)
-
•
Boston Medical Center Addiction Chat Live (Boston Medical Center, 2018)
-
•
Continuum of Care ECHO: Inpatient treatment programs and Methadone providers (Boston Medical Center, 2019b)
-
•
Boston Medical Center Office Based Addiction Treatment Clinical Guidelines (Boston Medical Center, 2019c)
-
•
American College of Emergency Physicians Addressing the Opioid Stigma in the Emergency Department (American College of Emergency Physicians, 2020b)
-
•
Initiating Buprenorphine treatment in detoxification settings (Stein et al., 2020)
-
•
Association between mortality rates and medication and residential treatment (Walley et al., 2020)
-
•
Institute for Health and Recovery Maternal Opioid Use During Pregnancy Toolkit (Institute for Health and Recovery Massachusetts Perinatal Quality Collaborative, 2018)
-
•
Adolescent Substance Use and Addiction Program – Primary Care (Levy et al., 2018)
-
•
Integrating BUP treatment in HIV primary care settings (Target HIV, 2019)
-
•
Case Western Intensive Course Series continuing medical education on controlled substance prescribing and buprenorphine (Case Western University School of Medicine, 2019)S
tate-Specific Resources
|
Adding/expanding MOUD treatment in Criminal Justice settings (e.g., pre-trial, jail, prison, probation, parole) (Binswanger, 2019; Green et al., 2018; Marsden et al., 2017; Moore et al., 2019; Rich et al., 2015) |
|
Expanding access to MOUD treatment through telemedicine, interim buprenorphine or methadone, or medication units |
-
•
Medication units: electronic-Code of Federal Regulations - 8.11 (Office of the Federal Register and Government Publishing Office, 2019b; Substance Abuse and Mental Health Services Administration, 2015b)
-
•
Interim methadone: electronic-Code of Federal Regulations – 8.11 (Newman, 2014; Office of the Federal Register and Government Publishing Office, 2019a; Schwartz et al., 2006)
-
•
Interim buprenorphine (Office of the Federal Register and Government Publishing Office, 2019b; Sigmon et al., 2016)
-
•
Low Barrier Tele-Buprenorphine (Harris et al., 2020)
-
•
MOUD Bridge Programs (Snow et al., 2019)
-
•
San Francisco Street Medicine Team (Carter et al., 2019)
-
•
Telemedicine&Prescribing Buprenorphine for the Treatment of Opioid Use Disorder (U.S. Department of Health and Human Services, 2018)
-
•
Project “Support for Hospital Opioid Use Treatment” Webinar on Telemedicine and MOUD Treatment (Project SHOUT and California Health Care Foundation, 2018)
|
|
|
Linkage Programs (all relevant settings) |
Within (or initiated within) Service Settings
Within Outreach/Field Settings
Peer Navigation
Referral Only
|
Starting individuals on MOUD as an adjunct to linkage programs (all relevant settings) (Busch et al., 2017; Cushman et al., 2016; D’Onofrio et al., 2015; Gordon et al., 2017; Weinstein et al., 2018; Zaller et al., 2013) |
Within (or initiated within) Service Settings
-
•
SAMHSA TIP 63: Medications for OUD (Substance Abuse and Mental Health Services Administration, 2020d)
-
•
California Bridge (California Department of Health Care Services, 2018) and Project “Support for Hospital Opioid Use Treatment” (Project SHOUT and California Health Care Foundation, 2018)
-
•
National Commission on Correctional Healthcare Jail-based Medication Assisted Treatment (National Commission on Correctional Healthcare, 2018)
-
•
SAMHSA: Use of Medication Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings (Substance Abuse and Mental Health Services Administration, 2019e)
-
•
“Principles of Drug Abuse Treatment of Criminal Justice Populations: A Research-Based Guide”(National Institute on Drug Abuse, 2014a)
-
•
SAMHSA: Clinical use of extended-release injectable naltrexone in the treatment of Opioid Use Disorder: A Brief Guide (Substance Abuse and Mental Health Services Administration, 2015a)
-
•
Opioid Response Network (American Academy of Addiction Psychiatry and State Targeted Response Technical Assistance Consortium, 2018)
-
•
Yale School of Emergency Medicine: Emergency Department-Initiated Buprenorphine (Yale School of Medicine, 2019)
-
•
American College of Emergency Physicians Emergency Quality Network Opioid Toolkit (American College of Emergency Physicians, 2020a)
-
•
SAMHSA National Helpline (Substance Abuse and Mental Health Services Administration, 2020e)
-
•
Harm Reduction agencies as potential site for buprenorphine treatment (Fox et al., 2015)
-
•
Addiction consultation services – Linking Hospitalized patients to outpatient addiction treatment (Trowbridge et al., 2017)
-
•
A Transitional Opioid program to Engage Hospitalized Drug Users (Shanahan et al., 2010)
-
•
MOUD Bridge Programs (Snow et al., 2019)
-
•
San Francisco Street Medicine Team (Carter et al., 2019)
|
|
|
Enhancement of clinical delivery approaches that support engagement and retention (Plater-Zyberk et al., 2012; Substance Abuse and Mental Health Services Administration, 2020) |
|
Use of virtual retention approaches (e.g., mobile, web, digital therapeutics) (Pear Therapeutics, 2020; Substance Abuse and Mental Health Services Administration, date unknown) |
|
Utilize retention care coordinators |
|
Mental health and polysubstance use treatment integrated into MOUD care (Krawczyk et al., 2017; Sullivan et al., 2010) |
-
•
Preventing Addiction Related Suicide (Voss et al., 2013)
-
•
SAMHSA: General Principles for the Use of Pharmacological Agents To Treat Individuals With Co-Occurring Mental and Substance Use Disorders (Substance Abuse and Mental Health Services Administration, 2012a)
-
•
SAMHSA: TIP 42: Substance Abuse Treatment for Persons With Co-Occurring Disorders (Substance Abuse and Mental Health Services Administration, 2020f)
-
•
SAMHSA: Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress Disorder and Co-Occurring Opioid Use Disorders (Substance Abuse and Mental Health Services Administration, 2012b)
-
•
American Psychiatric Association Learning Center: Treating Co-Occurring Depression and Opioid Use Disorder: A Case Discussion (American Psycihatric Association, 2015)
-
•
Integrated Group Therapy bipolar and substance use disorders (Weiss and Connery, 2011)
-
•
Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2018)
-
•
Contingency Management (Carroll and Weiss, 2017) combined with Community Reinforcement Approach; Promoting Awareness of Motivational Incentives (Center for the Application of Substance Abuse Technologies, 2019)
-
•
Addiction Technology Transfer Center Network Motivational Interviewing Training (Addiction Technology Transfer Center Network, 2019)
-
•
Providers Clinical Support System Webinars (Providers Clinical Support System, 2019a)
-
•
National Institute on Drug Abuse Health Principles of Drug Addiction Treatment: A Research-Based Guide (National Institute on Drug Abuse, 2018)
-
•
SAMHSA In Brief: Substance Use and Suicide: A Nexus Requiring A Public Health Approach (Substance Abuse and Mental Health Services Administration, 2015c)
-
•
SAMHSA: TIP 50: Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment (Substance Abuse and Mental Health Services Administration and Center for Substance Abuse Treatment, 2009)
-
•
National Institute of Mental Health Suicide Prevention Website (National Institute of Mental Health, 2019)
-
•
Suicide Prevention Resource Center (Suicide Prevention Resource Center, 2019)
|
Reducing barriers to housing, transportation, childcare and accessing other community benefits for people with opioid use disorder |
|